Welcome to our dedicated page for Fate Therapeutic SEC filings (Ticker: FATE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Fate Therapeutics files SEC reports that document its clinical-stage biopharmaceutical business and its iPSC-derived cellular immunotherapy pipeline for cancer and autoimmune diseases. Current reports furnish operating results and business updates, including disclosures on FT819, FT836 and other off-the-shelf CAR T-cell programs, FDA-related development matters, clinical presentations, and costs associated with restructuring actions.
Proxy and current-report filings cover board and compensation governance, equity-plan matters, Regulation FD disclosures, and capital-structure details for FATE common stock listed on the Nasdaq Global Market. The filings also record material events affecting operations and public-company reporting obligations.
BlackRock, Inc. filed Amendment No. 8 on a Schedule 13G/A reporting beneficial ownership of 2,194,284 shares of Fate Therapeutics common stock, representing 1.9% of the class as reported on 06/30/2026. The filing lists sole voting and sole dispositive power for 2,194,284 shares. The filing is signed by Spencer Fleming as Managing Director on 07/08/2026.
Fate Therapeutics reported that an entity associated with Redmile Group received a new stock option award linked to board service. The option covers 87,900 shares of common stock at an exercise price of $2.06 per share and expires on June 12, 2036. It was granted to director Michael Lee for his role on the board, but, under Redmile’s policies, he holds it as a nominee for the sole benefit of Redmile, which has the economic and voting rights. The option will vest in full on the earlier of June 12, 2027 or the date of the company’s 2027 annual stockholder meeting, subject to Lee’s continued board service. Redmile and principal Jeremy Green disclaim beneficial ownership except to any pecuniary interest they may have.
Fate Therapeutics director Michael Stewart Lee received a grant of stock options as compensation for his board service. The award covers 87,900 stock options to purchase common shares at an exercise price of $2.06 per share, expiring on June 12, 2036. The options vest in full on the earlier of June 12, 2027 or the company’s 2027 annual stockholders’ meeting, subject to his continued board service. The grant is held by Lee as a nominee for Redmile Group, LLC, which holds the economic and voting rights, and both Lee and Redmile parties disclaim beneficial ownership except to the extent of any pecuniary interest.
Fate Therapeutics director Yuan Xu received a new stock option grant as board compensation. The award covers 87,900 shares of common stock at an exercise price of $2.06 per share and is held directly. Following this grant, Xu holds options on 87,900 underlying shares.
The option vests and becomes exercisable on the earlier of June 12, 2027 or the date of Fate Therapeutics’ 2027 annual stockholder meeting, as long as Xu continues serving on the board. This is a non-employee director equity grant under the company’s compensation policy, not an open-market purchase or sale.
FATE Therapeutics director Karin Jooss received a routine stock option grant as part of non-employee director compensation. She was awarded options for 87,900 shares of common stock at an exercise price of $2.06 per share, expiring in 2036. The options vest on the earlier of June 12, 2027 or the company’s 2027 annual stockholder meeting, subject to continued board service, and represent compensation rather than an open-market purchase or sale.
Fate Therapeutics director Robert S. Epstein received a grant of stock options covering 87,900 shares of common stock. The options have an exercise price of $2.06 per share and expire on June 12, 2036. This award was issued under the company’s Amended and Restated Non-Employee Director Compensation Policy as an annual equity grant for non-employee directors.
The options will vest and become exercisable on the earlier of June 12, 2027 or the date of Fate Therapeutics’ 2027 Annual Meeting of Stockholders, as long as Epstein continues to serve on the board. After this grant, he holds 87,900 options directly.
Fate Therapeutics director Shefali Agarwal received a new stock option grant covering 87,900 shares of common stock. The option has an exercise price of $2.06 per share and expires on June 12, 2036. It will vest and become exercisable on the earlier of June 12, 2027 or the company’s 2027 Annual Meeting of Stockholders, contingent on her continued board service. Following this grant, she holds options on 87,900 shares directly.
FATE Therapeutics director Matt Abernethy received a new stock option grant covering 87,900 shares of common stock. The option has an exercise price of $2.06 per share and expires on June 12, 2036.
The grant was made under the company’s Amended and Restated Non-Employee Director Compensation Policy, which provides annual equity awards on the date of the Annual Meeting of Stockholders. These options vest and become exercisable on the earlier of June 12, 2027 or the date of the 2027 Annual Meeting, as long as Abernethy continues to serve on the board.
Fate Therapeutics director William H. Rastetter received a grant of stock options covering 87,900 shares of Common Stock. The options have an exercise price of $2.06 per share and expire on June 12, 2036.
The grant was made under the company’s Amended and Restated Non-Employee Director Compensation Policy, which provides annual equity awards to non-employee directors on the date of the Annual Meeting of Stockholders. These options vest and become exercisable on the earlier of June 12, 2027 or the date of the 2027 Annual Meeting of Stockholders, subject to his continued service on the Board. Following this grant, he holds 87,900 options according to this filing.
Fate Therapeutics director Laura Hamill received a grant of stock options to acquire 175,800 shares of Common Stock. The options have an exercise price of $2.06 per share and expire on June 12, 2036. This grant was made under the company’s Amended and Restated Non-Employee Director Compensation Policy, which provides equity upon a director’s appointment or election. The options vest in 36 equal monthly installments starting on June 12, 2026 and will be fully vested on June 12, 2029, contingent on Hamill’s continued service on the Board.